LISA MEYER: Open Payments
NPI 1912208323 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,894 in 120 payments from 13 companies in 2025. Trend: 2023 $1,819 · 2024 $2,486 · 2025 $1,894
Food & beverage: $1,894
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $271 |
| ABBVIE INC. | 23 | $250 |
| Teva Pharmaceuticals USA, Inc. | 14 | $234 |
| Alkermes, Inc. | 14 | $234 |
| Neurocrine BioSciences, Inc. | 13 | $222 |
| Vanda Pharmaceuticals Inc. | 11 | $207 |
| Lundbeck LLC | 10 | $172 |
| Corium, LLC | 8 | $127 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
Products named: REXULTI, VRAYLAR, ARISTADA, INGREZZA, UZEDY, Azstarys, ABILIFY MAINTENA, FANAPT.
Industry payments across IA — which companies pay providers there.
